Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Nov / A Grueling Environment
Manufacture Bioprocessing - Upstream & Downstream Technology and Equipment Translational Science Biopharma Facilities & Equipment Technology & Manufacturing Development & Clinical

A Grueling Environment

By Phil Williams 11/18/2020 1 min read Longer Read (pre 2022)

Share

The altered environment of spaceflight causes changes in many biological processes that have evolved to function in the 1G, radiation-free, temperate, saline environment of Earth. The immediate change to the body is caused by the environment of microgravity, where astronauts are in constant freefall as they orbit the globe. This environment causes redistribution of fluids in the body, in particular the blood, which is no longer pulled towards the feet and away from the head. The body compensates for this unnatural pooling in the upper half of the body by then reducing the volume of the blood. These changes in fluid distribution and blood volume all cause immediate changes to pharmacokinetics/pharmacodynamics (PK/PD). Studies on the SpaceLab (the laboratory that flew in the bay of the Space Shuttle), for example, have shown that the rate of absorption (measured in saliva) of paracetamol and scopolamine/dexedrine from tablets were double after one day of space flight, and almost halved after two. Longer term changes caused by microgravity include muscle atrophy, insulin receptor desensitization (astronauts can be clinically diabetic after 30 days of spaceflight), retinopathy, and decalcification of bone (and the consequent deposition of calcium elsewhere, often as kidney stones).

It has also been shown that stem cells change in microgravity. They tend to remain undifferentiated in flight, but they differentiate on return to Earth along one lineage far quicker than normal. Bacteria are also shown to behave differently. Whether due to changes in the mechanics of membranes evident in parabolic flight or cell surface receptor recruitment or other factors, bacteria have been shown to be more resistant to antibiotics and, for other reasons, antibiotics are also less effective.

With changes to bacteria, there are also changes to the gut microbiome. Enzyme activity has been shown to be affected, meaning that food and medicines are absorbed and processed differently during spaceflight. With the now-known link between the gut and the brain, and the link between the state of the microbiome and mental health, there are many interlinked and complex issues that need to be researched and understood when it comes to long-term spaceflight. And issues around mental health will only be compounded by the obvious pressures of confinement, social isolation, stress, and changes in circadian rhythm.

All of these issues, and more, come to the fore when considering a mission to Mars. Such a mission, described by NASA’s Design Reference Architecture 5.0, on which Andrew Weir wrote the book ‘The Martian,’ would be around three years with a crew of six. It has been estimated that the chance of serious illness or death in an activity such as spaceflight is 0.06 per-man-per-year. The chance of such an incident in one of six crew in their three-year mission to Mars is 67 percent. There is a 20 percent chance that half the crew will suffer. We must find a way to treat these explorers if such a mission is to take place. They cannot take every medicine with them on the journey.

Bringing things closer to home, the often dramatic and largely unpredictable rapid changes to PK/PD on spaceflight could produce real and current problems in the area of space tourism. For paracetamol, a doubling of the rate of absorption and maximum plasma concentration after a few hours of flight is not a huge problem. But if the astronaut took a drug with a narrow therapeutic window, then such a change could be fatal. Until now, astronauts are selected based on their physical and mental fitness (and on the payroll of national governments). But with the advent of space tourism, where the financial drivers and considerations differ, the considerations of medication become greater. Who will license? Who will authorize? Who will prescribe? Who will provide the medical information for space medication? This area – although not covered in this feature – is something that my colleague, Li Shean Toh, at the University of Nottingham, is developing.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Phil Williams

More Articles by Phil Williams

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Pass Me a Bottle Opener
Bioprocessing - Upstream & Downstream
Pass Me a Bottle Opener

December 1, 2014

0 min read

Upstream processes in biopharma manufacturing are growing ever more efficient; conversely, downstream processing is increasingly a bottleneck. Can a new generation of chromatography techniques and technologies get things moving again?

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Biotech Versus the Superbugs
Bioprocessing - Upstream & Downstream Drug Discovery
Biotech Versus the Superbugs

April 7, 2025

6 min read

Meet one company and its new drug candidate in the fight against gram-negative bacterial infections.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.